Mirati Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.03.18	Mirati Therapeutics To Present At Upcoming Healthcare Conferences (PR Newswire)
01.03.18	Forbes School of Business & Technology Human Resources Program Named a 2018 Leadership Excellence and Development Award Winner by HR.com (PR Newswire)
08.02.18	Mirati Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference (PR Newswire)
27.12.17	Famous Five: Did You Invest In These 5 Biotech Stocks? (RTTNews)
13.11.17	Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs (PR Newswire)
01.11.17	Mirati Therapeutics Reports Third Quarter 2017 Financial Results (PR Newswire)
12.10.17	Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients (PR Newswire)
19.09.17	Mirati Therapeutics To Present At Upcoming Healthcare Conferences (PR Newswire)
14.09.17	Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer (PR Newswire)
07.09.17	SYSPRO is Again Named a Leader in 2017 Nucleus Research ERP Technology Value Matrix (PR Newswire)
30.08.17	Mirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The 2017 Citi Biotech Conference (PR Newswire)
03.08.17	Mirati Therapeutics Reports Second Quarter 2017 Financial Results (PR Newswire)
06.07.17	Mirati Therapeutics To Host Key Opinion Leader Breakfast On Immuno-oncology Combinations On July 11 In New York (PR Newswire)
20.06.17	Gainers & Losers Of June 19: ARNA, NVDQ, CLVS, RWLK, CLSN... (RTTNews)
31.05.17	Mirati Therapeutics To Present At The 2017 Jefferies Global Healthcare Conference (PR Newswire)
18.05.17	Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN... (RTTNews)
04.05.17	Mirati Therapeutics Reports First Quarter 2017 Financial Results (PR Newswire)
09.03.17	Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016 (PR Newswire)
13.02.17	Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference (PR Newswire)
09.01.17	MRTX Prices Offering At $5.60/Share (RTTNews)
05.01.17	Mirati Therapeutics Announces Proposed Public Offering of Common Stock (PR Newswire)
05.01.17	Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs (PR Newswire)
07.12.16	From Hype To Flop: 10 Biotech Stops That Let Down Investors In 2016 (RTTNews)
10.03.16	It's One Up For AKBA, CYNA Under Close Watch, Busy Days Ahead For APRI (RTTNews)
16.09.15	Mirati Therapeutics Prices Offering Of 2.25 Mln Shares At $45.00/shr (RTTNews)
11.08.14	FDA Grants Orphan Drug Designation To Mirati's Lymphoma Drug Mocetinostat (RTTNews)
18.06.14	CANF In For The Long Haul, CLTX Awaits Busy Q4, DSCO Gets Richer, ECYT Slumps (RTTNews)
17.06.14	Mirati Therapeutics' Mocetinostat Granted FDA Orphan Drug Designation For MDS (RTTNews)
17.03.14	Mirati Therapeutics Q4 Loss Widens - Quick Facts (RTTNews)
16.10.13	Mirati Therapeutics Announces Public Offering Of Common Stock (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	26.97	0.97 %	K V
Swiss Re	129.55	0.82 %	K V
Zurich Insur Gr	536.80	0.71 %	K V
CieFinRichemont	135.70	0.67 %	K V
Holcim	86.60	0.58 %	K V
Sonova Hldg	295.20	-0.14 %	K V
Nestle	73.80	-0.24 %	K V
Sika	212.60	-0.28 %	K V
Alcon	75.76	-0.34 %	K V
Geberit	511.00	-0.62 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Mirati Therapeutics Inc

Aktien Top/Flop

Mirati Therapeutics Peer Group Nachrichten

Meistgelesene Nachrichten